CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company, ...

Preclinical data support Abalos’ first-in-class approach of safely harnessing the immunostimulatory and anti-tumoral properties of ...

Study’s Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending ...

Investing.com -- CERo Therapeutics (NASDAQ:CERO), a T cell therapy biotech company, is open to licensing deals or a potential sale while awaiting data on its lead asset, according to Axios, citing CEO ...

Seven UCSF investigators are receiving the prestigious award for their research from the National Institutes of Health.

A next-generation cancer vaccine has shown stunning results in mice, preventing up to 88% of aggressive and ...

The super adjuvant vaccine also protected against the spread of cancer to the lungs. When exposed to melanoma cells systemically, which mimics how cancer metastasizes, none of the ...

A new research paper was published in Volume 16 of Oncotarget on October 6, 2025, titled "ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL ...

ACTM-838 showed durable anti-tumor efficacy in multiple murine tumor models and synergized with anti-PD1 therapy in ...

Fast Track Designation underscores the promise of Werewolf’s INDUKINE™ platform. WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Compan ...

Board-certified oncologist who brings over 20 years of senior clinical development experience across large pharmaceutical, biotechnology and Clinical Research OrganizationsLONDON--(BUSINESS ...